Toggle navigation
Menu
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
73°
Search
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Local Weather
News
Sports
Entertainment
Calendar
Games
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Town & Gown
Subscribe
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Eiger Biopharma
(NQ:
EIGR
)
11.02
USD
-0.84 (-7.08%)
Official Closing Price
Updated: 6:03 PM EST, Jan 15, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All news about Eiger Biopharma
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Eiger BioPharmaceuticals Appoints Regulatory Expert and Industry Veteran Christine Murray, MS, RAC to its Board of Directors
January 07, 2019
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare and ultra-rare diseases, announced today the appointment of Christine Murray, MS,...
From
PR Newswire
Report: Exploring Fundamental Drivers Behind Cronos Group, Henry Schein, Argo Group International, Eiger BioPharmaceuticals, China Automotive, and Moleculin Biotech — New Horizons, Emerging Trends, an
December 30, 2018
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Cronos Group Inc....
From
GlobeNewswire News Releases
Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies
December 19, 2018
- Survival Benefit in Children with Progeria Published in JAMA 2018
From
PR Newswire
Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection
December 18, 2018
- Phase 3 HDV "D-LIVR" International Study Initiating
From
PR Newswire
Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection
December 17, 2018
- Phase 3 HDV "D-LIVR" International Study Initiating
From
PR Newswire
Eiger BioPharmaceuticals Reports on 2018 R&D Day
December 11, 2018
-- Late Stage Rare and Ultra-Rare Disease Pipeline Advancing
From
PR Newswire
Top Buys by Directors: Mayer III's $248.8K Bet on EIGR
December 04, 2018
The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company...
Tags
Stocks
From
Market News Video
Eiger BioPharmaceuticals to Host R&D Day in New York City
December 04, 2018
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced it will host an R&D Day on...
From
PR Newswire
The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO
December 03, 2018
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting ...
Tags
RHHBY
Benzinga
AMPH
From
Benzinga
Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer
December 03, 2018
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced the appointment of Sri Ryali as...
From
PR Newswire
Eiger BioPharmaceuticals (EIGR) Shares Cross Above 200 DMA
December 03, 2018
In trading on Monday, shares of Eiger BioPharmaceuticals Inc (EIGR) crossed above their 200 day moving average of $11.12, changing hands as high as $11.22 per share. Eiger BioPharmaceuticals Inc shares...
Tags
Stocks
From
Market News Video
Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies
December 03, 2018
- Plans to File NDA in 2019
From
PR Newswire
36 Biggest Movers From Friday
November 25, 2018
Gainers Orchids Paper Products Company (NYSE: TIS) shares climbed 164.71 percent to close at $1.80 after the company announced a ...
Tags
STG
News
Market News
From
Benzinga
Analysis: Positioning to Benefit within Artisan Partners Asset Management, Gamco Investors, Eiger BioPharmaceuticals, Waddell & Reed Financial, AmpliPhi Biosciences, and Limbach — Research Highlights
November 23, 2018
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Artisan Partners Asset...
From
GlobeNewswire News Releases
Eiger to Participate in Piper Jaffray Healthcare Conference
November 19, 2018
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that David Cory, President and CEO, will present...
From
PR Newswire
Eiger Bio Reports Third Quarter 2018 Financial Results
November 09, 2018
- HDV Phase 3 D-LIVR study start in 2018 and Progeria NDA planned in 2019
From
PR Newswire
Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock
October 23, 2018
Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the accelerated development and commercialization of targeted therapies for rare and ultra-rare...
From
PR Newswire
The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares
October 23, 2018
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks None of the stocks hit ...
Tags
SCYX
FLXN
BLCM
From
Benzinga
Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
October 22, 2018
Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that it has commenced an underwritten public...
From
PR Newswire
Eiger BioPharmaceuticals Receives FDA Rare Pediatric Disease (RPD) Designation for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies and Plans NDA Filing in 2019
October 22, 2018
- Designation Enables Priority Review Voucher Eligibility Upon NDA Approval
From
PR Newswire
Eiger BioPharmaceuticals to Participate at BTIG Biotech Conference
October 18, 2018
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced the Eiger management team will participate and...
From
PR Newswire
The Daily Biotech Pulse: Novartis Buys Endocyte, Proteostasis Positive Cystic Fibrosis Trial, 2 IPOs
October 18, 2018
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting ...
Tags
MBRX
Biotech
NVS
From
Benzinga
46 Biggest Movers From Yesterday
October 17, 2018
Gainers Yulong Eco-Materials Limited (NASDAQ: YECO) shares climbed 571.05 percent to close at $10.20 on Wednesday after the ...
Tags
CZR
BLNK
JP
From
Benzinga
Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection
October 17, 2018
- Lambda Antiviral Activity Demonstrated in HDV Infection
From
PR Newswire
36 Stocks Moving In Wednesday's Mid-Day Session
October 17, 2018
Gainers Yulong Eco-Materials Limited (NASDAQ: YECO) shares jumped 134 percent to $3.557 after the company earlier announced it is ...
Tags
Top Gainers
IBP
Losers
From
Benzinga
Morning Call For Wednesday, Oct. 17
October 17, 2018
Dec E-mini S&Ps (ESZ18 -0.31%) this morning are down -0.25% ahead of the FOMC meeting. European stocks are down -0.09%, led by losses in automakers.
Tags
Stocks / Equities
Bonds
Commodities
From
Blogs - TalkMarkets
The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise
October 17, 2018
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting ...
Tags
IPCI
ENDP
EVLO
From
Benzinga
Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)
October 16, 2018
- Primary and Secondary Endpoints Achieved with Statistical Significance
From
PR Newswire
Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint
October 16, 2018
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced Phase 2 ULTRA study results in primary and...
From
PR Newswire
Eiger BioPharmaceuticals to Participate in Investor Conferences
September 25, 2018
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that David Cory, President and...
From
PR Newswire
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.